Astrocytes is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
Astrocytes[1] are the most abundant glial cells in the [central nervous system], constituting approximately 20–40% of the total brain cell population. Named for their star-shaped morphology (from the Greek astron, meaning star), astrocytes perform a remarkable diversity of essential functions including metabolic support of neurons, maintenance of the blood-brain barrier, regulation of neurotransmitter homeostasis, modulation of synaptic transmission, and coordination of cerebral blood flow. Once considered passive structural scaffolding, astrocytes are now recognized as active participants in neural circuit function and critical determinants of brain health and disease (Bhatt & Bhatt, 2019; Allen & Bhatt, 2017).
In neurodegenerative diseases, astrocytes undergo reactive changes (astrogliosis) that profoundly alter their functional properties. Reactive astrocytes can adopt neurotoxic (A1) or neuroprotective (A2) phenotypes, and the balance between these states significantly influences disease progression in [Alzheimer[3]'s disease], Parkinson's disease, ALS, Huntington's disease, and multiple sclerosis. Plasma and CSF levels of [glial fibrillary acidic protein (GFAP — an astrocyte-specific intermediate filament — have emerged as important biomarkers for tracking astrocyte reactivity and neurodegeneration (Edison et al., 2024).
¶ Morphology and Classification
Astrocytes[1] exhibit considerable morphological and functional diversity depending on their brain region, developmental stage, and disease context:
- Protoplasmic astrocytes: Found predominantly in gray matter, these cells have dense, highly branched processes that tile the brain parenchyma. Each human protoplasmic astrocyte occupies a territory covering approximately 2 million synapses.
- Fibrous astrocytes: Located in white matter, with longer, less branched processes aligned along axon bundles. They support [myelination] and axonal integrity.
- Radial glia: Present during embryonic development, serving as neural progenitor cells and scaffolds for neuronal migration. In the adult brain, radial glia-like cells persist in neurogenic niches of the hippocampus and subventricular zone.
- Reactive astrocytes: Emerge in response to injury, infection, or neurodegeneration. Characterized by hypertrophied morphology, increased GFAP expression, and altered functional profiles.
Astrocyte processes contact blood vessels at specialized structures called endfeet, wrap around synapses to form the tripartite synapse, and interconnect with other astrocytes through gap junctions (connexin 30 and connexin 43), forming a syncytial network that enables coordinated signaling across brain regions.
Astrocytes[1] are central to brain energy metabolism through the astrocyte-neuron lactate shuttle:
- Glycogen storage: Astrocytes[1] are the primary glycogen stores of the brain, providing lactate to neurons during periods of high activity via monocarboxylate transporters
- Glucose uptake: Astrocytic endfeet uptake glucose from the blood through GLUT1 transporters and metabolize it glycolytically
- Lipid metabolism: Astrocytes[1] synthesize and distribute lipids essential for [neuronal] membrane integrity and [myelin] maintenance. Lipid accumulation in astrocytes is increasingly recognized as a pathological feature of neurodegeneration
¶ Blood-Brain Barrier Maintenance
Astrocytic endfeet ensheath approximately 99% of the brain vasculature and are critical components of the neurovascular unit:
- Induce and maintain blood-brain barrier tight junction integrity via release of Sonic Hedgehog and angiopoietin-1
- Regulate cerebral blood flow through calcium-dependent release of vasoactive mediators (prostaglandins, nitric oxide, potassium ions)
- Express aquaporin-4 (AQP4) water channels at perivascular endfeet, essential for the glymphatic system that clears metabolic waste including [amyloid-β] and tau] during sleep
Astrocytes[1] maintain the excitatory-inhibitory balance essential for neural circuit function:
- Glutamate uptake: Astrocytic glutamate transporters (GLT-1/EAAT2 and GLAST/EAAT1) remove excess glutamate from the synaptic cleft, preventing excitotoxicity
- Glutamine-glutamate cycle: Astrocytes[1] convert glutamate to glutamine via glutamine synthetase, then shuttle glutamine back to neurons for neurotransmitter resynthesis
- GABA recycling: Astrocytes[1] uptake GABA and convert it through the GABA shunt
- Ion homeostasis: Spatial buffering of extracellular potassium via Kir4.1 channels
At the tripartite synapse (presynaptic terminal, postsynaptic spine, and astrocytic process), astrocytes actively modulate synaptic transmission:
- Release gliotransmitters (glutamate, D-serine, ATP) that influence synaptic strength and plasticity
- Regulate synapse formation, maturation, and elimination through thrombospondins, hevin, and SPARC
- Coordinate neural circuit activity through calcium waves propagated via gap junctions
- Modulate NMDA receptor receptor] receptor] function through D-serine co-agonist supply
¶ A1 and A2 Reactive Phenotypes
Single-cell transcriptomic and proteomic studies have revealed that reactive astrocytes adopt distinct functional states (Liddelow et al., 2017):
- A1 (neurotoxic) astrocytes: Induced by microglia.
Glial fibrillary acidic protein (GFAP), a type III intermediate filament specific to astrocytes, is released into biofluids during astrogliosis and has emerged as a leading biomarker for neurodegenerative diseases:
- Plasma GFAP is elevated in preclinical [Alzheimer[3]'s disease], correlating with amyloid positivity, brain atrophy, and tau] pathology] (Pereira et al., 2024)
- CSF GFAP levels reflect astrocyte reactivity around amyloid plaques
- Plasma GFAP may serve as a screening biomarker for amyloid status in clinical practice
Astrocytes[1] undergo profound changes in [Alzheimer[3]'s disease] that contribute to both disease progression and compensation ([Astrocyte Reactivity in AD):
- Reactive astrogliosis: GFAP and vimentin upregulation, morphological hypertrophy, and proliferation near [amyloid plaques]
- Amyloid-β metabolism: Astrocytes[1] phagocytose amyloid-β aggregates and transport soluble Aβ across the blood-brain barrier. However, excessive amyloid uptake impairs astrocyte function
- Tau propagation: Reactive astrocytes may facilitate tau] spread between brain regions via exosome release
- Glymphatic dysfunction: Loss of AQP4 polarization at perivascular endfeet impairs waste clearance
- [Calcium dysregulation]: Altered calcium signaling disrupts glutamate recycling and neurovascular coupling
- Metabolic failure: Impaired lactate transport and glucose metabolism contribute to neuronal energy deficits
In Parkinson's disease, astrocyte dysfunction contributes to dopaminergic neuron vulnerability in the substantia nigra:
In ALS, astrocytes actively contribute to motor neuron degeneration:
- Mutant SOD1-expressing astrocytes are selectively toxic to motor neurons through non-cell-autonomous mechanisms
- Impaired glutamate clearance due to GLT-1 downregulation causes chronic excitotoxicity
- TDP-43 aggregation in astrocytes disrupts their homeostatic functions
- Release of pro-inflammatory mediators and reduction of neurotrophic support
Astrocyte dysfunction in Huntington's disease involves:
- Mutant huntingtin aggregation in astrocytes disrupting transcription of key genes including GLT-1 and Kir4.1
- Impaired potassium buffering increasing neuronal excitability in the striatum
- Reduced glutamate uptake contributing to excitotoxic striatal neuron loss
Astrocytes[1] represent promising and increasingly explored therapeutic targets:
- Modulating astrocyte reactivity: Converting A1 neurotoxic astrocytes to A2 neuroprotective phenotypes, potentially through blocking microglial activation signals
- Enhancing amyloid-β clearance: Boosting astrocytic phagocytosis and AQP4-mediated glymphatic clearance
- Restoring glutamate homeostasis: Upregulating GLT-1/EAAT2 expression using compounds like ceftriaxone
- Gene therapy approaches: AAV-mediated delivery of therapeutic genes specifically to astrocytes using GFAP promoters
- Metabolic restoration: Enhancing astrocytic lactate production and transport to support neuronal energy metabolism
- JAK-STAT pathway inhibition: Blocking the JAK-STAT3 signaling axis that drives neurotoxic reactive astrogliosis
- Astrocyte heterogeneity: Single-cell transcriptomics revealing region-specific and disease-specific astrocyte subtypes
- **Astrocyte-microglia, N. J., & Lyons, D. A. (2018). Glia as architects of central nervous system formation and function. Science, 362(6411), 181–185. PubMed
- PubMed - Literature database
- NCBI - National Center for Biotechnology Information
The study of Astrocytes has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- [Sofroniew, M. V., & Vinters, H. V. (2010]. Astrocytes[1]: biology and pathology. Acta Neuropathologica, 119(1), 7–35. PubMed)
- PubMed
- [Hasel, P., et al. (2021]. Neuroinflammatory astrocyte subtypes in the mouse brain. Nature Neuroscience, 24(10), 1475–1487. PubMed)
- [Edison, P., et al. (2024]. Astroglial activation: current concepts and future directions. Alzheimer[3]'s & Dementia, 20(5), 3483–3496. PubMed)
- [Pereira, J. B., et al. (2024]. Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles. Brain, 147(5), 1557–1568. PubMed)
- [Escartin, C., et al. (2021]. Reactive astrocyte nomenclature, definitions, and future directions. Nature Neuroscience, 24(3), 312–325. PubMed)
- [Verkhratsky, A., & Bhatt, D. L. (2018]. Astrogliopathology in neurological, neurodevelopmental and psychiatric disorders. Neurobiology of Disease, 111, 85–100. PubMed)
- [Khakh, B. S., & Bhatt, D. L. (2019]. The emerging nature of astrocyte diversity. Annual Review of Neuroscience, 42, 187–207. PubMed)
- [Pekny, M., et al. (2016]. Astrocytes[1]: a central element in neurological diseases. Acta Neuropathologica, 131(3), 323–345. PubMed)
- [Zamanian, J. L., et al. (2012]. Genomic analysis of reactive astrogliosis. The Journal of Neuroscience, 32(18), 6391–6410. PubMed)
- PubMed
- [Bhatt & Bhatt, 2019]https://pubmed.ncbi.nlm.nih.gov/30951645/)
- [Allen & Bhatt, 2017]https://pubmed.ncbi.nlm.nih.gov/29175534/)
- Bhatt & Bhatt, 2019
- Allen & Bhatt, 2017
- Edison et al., 2024
- Liddelow et al., 2017
- Pereira et al., 2024
- diseases — Disease with astrocyte-mediated motor neuron toxicity
- diseases — Disease with prominent reactive astrogliosis
- mechanisms — Inflammatory processes involving reactive astrocytes
- entities — Barrier maintained by astrocytic endfeet
- cell-types — Myelinating glial cells
- [/entities/microglia — Partnering glial cell in neuroinflammatory responses## Brain Atlas Resources
-
-
-
-
-
- microglia — Partnering glial cell in neuroinflammatory responses
-
-
-
-
-
- ALS — Disease with astrocyte-mediated motor neuron toxicity